non-small cell lung cancer
Conditions
Interventions
Case series:simultaneously integrated boost carbon ion radiation therapy
Sponsors
Shanghai Proton and Heavy Ion Center
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1) Sign the informed consent; 2) Aged 18-80 years old; 3) Be able to comply with the plan; 4) Primary tumor should be confirmed by cytology or histology test; 5) Cytological or histopathological diagnosis of non-small cell lung cancer; T>=3cmN0-3M0 (UICC/AJCC 8th edition staging); 6) Patients who were medically inoperable (evaluated by thoracic surgeon), or patients who refuse surgery; 7) ECOG score 0-2; 8) The expected survival time is more than 6 months; 9) Adequate organ function to meet the basic requirements for the treatment.
Exclusion criteria
Exclusion criteria: 1. The patient's disease has not been confirmed by pathology; 2. Has other malignant tumors and has not been controlled; 3. The side effects of previous treatments have not recovered, such as systemic chemotherapy or targeted therapy and other anti-cancer therapies interval <1 month; 4. The radiotherapy plan fails to meet the minimum dose coverage and dose volume limitation requirements of target area, or the radiation dose limitation of normal organs; 5. Had received thoracic radiation therapy or radioactive seed implantation in the past; 6. Cardiac pacemakers or other metal prostheses that may be interfered with normal functions by high-energy rays or may affect the dose in the radiation target area; 7. Pregnancy (confirmed by serum or urine -HCG) or lactation period; 8. HIV positive, including history of antiretroviral therapy; Chronic hepatitis B virus replication period; Hepatitis C active period; Syphilis active stage; 9. HBV positive, hepatitis virus replication stage, need to receive antiviral treatment, but because of the accompanying disease can not receive antiviral treatment; 10. There are serious complications that may affect the conduct of radiotherapy, including: (1) Acute infectious diseases; Or acute active exacerbation of chronic infection; (2) Unstable angina, congestive heart failure, myocardial infarction requiring hospitalization in the past 6 months; (3) Exacerbations of chronic obstructive pulmonary disease or other respiratory diseases requiring hospitalization; (4) Severely impaired immune function; (5) Hypersensitivity to radiation with ataxia telangiectasia; (6) during pregnancy or lactation; (7) Other diseases that may affect particle therapy; 11. No or limited capacity for civil conduct; 12. Abuse drugs or alcohol dependence, or have a history of mental illness, cannot understand the purpose of treatment or the study, or may hinder the completion of treatment; 13. Unwillingness/inability to sign informed consent; 14. Circumstances in which other physicians deem it inappropriate to participate in clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Local control rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression-free survival rate;Overall survival rate; | — |
Countries
China
Contacts
Public ContactJian Chen
Shanghai Proton and Heavy Ion Center
Outcome results
None listed